메뉴 건너뛰기




Volumn 94, Issue 6, 2013, Pages 646-650

Personalized network-based treatments in oncology

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BISPECIFIC ANTIBODY; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUORODEOXYGLUCOSE F 18; IMATINIB; LIGAND; MM 111; MM 141; MM 151; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

EID: 84888004863     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.171     Document Type: Article
Times cited : (23)

References (51)
  • 1
    • 79251478039 scopus 로고    scopus 로고
    • Genomics and the continuum of cancer care
    • Feero, W.G. et al. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340-350 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 340-350
    • Feero, W.G.1
  • 2
    • 84861639653 scopus 로고    scopus 로고
    • Traversing the genomic landscape of prostate cancer from diagnosis to death
    • Hieronymus, H. & Sawyers, C.L. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat. Genet. 44, 613-614 (2012).
    • (2012) Nat. Genet. , vol.44 , pp. 613-614
    • Hieronymus, H.1    Sawyers, C.L.2
  • 3
    • 41649114164 scopus 로고    scopus 로고
    • Enabling personalized cancer medicine through analysis of gene-expression patterns
    • DOI 10.1038/nature06915, PII NATURE06915
    • van't Veer, L.J. & Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008). (Pubitemid 351483370)
    • (2008) Nature , vol.452 , Issue.7187 , pp. 564-570
    • Van 't Veer, L.J.1    Bernards, R.2
  • 4
    • 73949136029 scopus 로고    scopus 로고
    • The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade
    • Weigelt, B., Baehner, F.L. & Reis-Filho, J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280 (2010).
    • (2010) J. Pathol. , vol.220 , pp. 263-280
    • Weigelt, B.1    Baehner, F.L.2    Reis-Filho, J.S.3
  • 5
    • 81555199640 scopus 로고    scopus 로고
    • Microarrays in the 2010s: The contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction
    • Colombo, P.E., Milanezi, F., Weigelt, B. & Reis-Filho, J.S. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 13, 212 (2011).
    • (2011) Breast Cancer Res. , vol.13 , pp. 212
    • Colombo, P.E.1    Milanezi, F.2    Weigelt, B.3    Reis-Filho, J.S.4
  • 6
    • 28844441230 scopus 로고    scopus 로고
    • Cell signaling: A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis
    • DOI 10.1126/science.1116598
    • Janes, K.A., Albeck, J.G., Gaudet, S., Sorger, P.K., Lauffenburger, D.A. & Yaffe, M.B. A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science 310, 1646-1653 (2005). (Pubitemid 41780781)
    • (2005) Science , vol.310 , Issue.5754 , pp. 1646-1653
    • Janes, K.A.1    Albeck, J.G.2    Gaudet, S.3    Sorger, P.K.4    Lauffenburger, D.A.5    Yaffe, M.B.6
  • 7
    • 34547146985 scopus 로고    scopus 로고
    • Network medicine-from obesity to the diseasome"
    • Barabási, A.L. Network medicine-from obesity to the "diseasome". N. Engl. J. Med. 357, 404-407 (2007).
    • (2007) N. Engl. J. Med. , vol.357 , pp. 404-407
    • Barabási, A.L.1
  • 8
    • 73949157882 scopus 로고    scopus 로고
    • Network-based drugs and biomarkers
    • Erler, J.T. & Linding, R. Network-based drugs and biomarkers. J. Pathol. 220, 290-296 (2010).
    • (2010) J. Pathol. , vol.220 , pp. 290-296
    • Erler, J.T.1    Linding, R.2
  • 9
    • 84860873858 scopus 로고    scopus 로고
    • Network medicine strikes a blow against breast cancer
    • Erler, J.T. & Linding, R. Network medicine strikes a blow against breast cancer. Cell 149, 731-733 (2012).
    • (2012) Cell , vol.149 , pp. 731-733
    • Erler, J.T.1    Linding, R.2
  • 10
    • 78650373804 scopus 로고    scopus 로고
    • Network medicine: A network-based approach to human disease
    • Barabási, A.L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).
    • (2011) Nat. Rev. Genet. , vol.12 , pp. 56-68
    • Barabási, A.L.1    Gulbahce, N.2    Loscalzo, J.3
  • 11
    • 84866122803 scopus 로고    scopus 로고
    • Navigating cancer network attractors for tumor-specific therapy
    • Creixell, P., Schoof, E.M., Erler, J.T. & Linding, R. Navigating cancer network attractors for tumor-specific therapy. Nat. Biotechnol. 30, 842-848 (2012).
    • (2012) Nat. Biotechnol. , vol.30 , pp. 842-848
    • Creixell, P.1    Schoof, E.M.2    Erler, J.T.3    Linding, R.4
  • 12
    • 41149167511 scopus 로고    scopus 로고
    • Network medicine
    • Pawson, T. & Linding, R. Network medicine. FEBS Lett. 582, 1266-1270 (2008).
    • (2008) FEBS Lett. , vol.582 , pp. 1266-1270
    • Pawson, T.1    Linding, R.2
  • 13
    • 0016430104 scopus 로고
    • Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
    • DeVita, V.T. Jr, Young, R.C. & Canellos, G.P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35, 98-110 (1975).
    • (1975) Cancer , vol.35 , pp. 98-110
    • DeVita Jr., V.T.1    Young, R.C.2    Canellos, G.P.3
  • 14
    • 84863651163 scopus 로고    scopus 로고
    • Combinatorial drug therapy for cancer in the post-genomic era
    • Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
    • (2012) Nat. Biotechnol. , vol.30 , pp. 679-692
    • Al-Lazikani, B.1    Banerji, U.2    Workman, P.3
  • 15
    • 84881483492 scopus 로고    scopus 로고
    • Evolutionary dynamics of cancer in response to targeted combination therapy
    • Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2, e00747 (2013).
    • (2013) Elife , vol.2
    • Bozic, I.1
  • 16
  • 17
    • 84860851412 scopus 로고    scopus 로고
    • Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
    • Lee, M.J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
    • (2012) Cell , vol.149 , pp. 780-794
    • Lee, M.J.1
  • 18
    • 54249155522 scopus 로고    scopus 로고
    • Network pharmacology: The next paradigm in drug discovery
    • Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
    • (2008) Nat. Chem. Biol. , vol.4 , pp. 682-690
    • Hopkins, A.L.1
  • 19
    • 69849115198 scopus 로고    scopus 로고
    • Therapeutically targeting ErbB3: A key node in ligandinduced activation of the ErbB receptor-PI3K axis
    • Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligandinduced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 (2009).
    • (2009) Sci. Signal. , vol.2
    • Schoeberl, B.1
  • 20
    • 84888007494 scopus 로고    scopus 로고
    • Pipeline
    • Merrimack Pharamaceuticals. Pipeline. http://merrimackpharma.com/ solutions/pipeline .
    • Merrimack Pharamaceuticals
  • 22
    • 73949083511 scopus 로고    scopus 로고
    • Oncogenic EGFR signaling networks in glioma
    • Huang, P.H., Xu, A.M. & White, F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2, re6 (2009).
    • (2009) Sci. Signal. , vol.2
    • Huang, P.H.1    Xu, A.M.2    White, F.M.3
  • 23
    • 84889002223 scopus 로고    scopus 로고
    • Network-based drug discovery by integrating systems biology and computational technologies
    • Leung, E.L., Cao, Z.W., Jiang, Z.H., Zhou, H. & Liu, L. Network-based drug discovery by integrating systems biology and computational technologies. Brief. Bioinformatics 14, 491-505 (2013).
    • (2013) Brief. Bioinformatics , vol.14 , pp. 491-505
    • Leung, E.L.1    Cao, Z.W.2    Jiang, Z.H.3    Zhou, H.4    Liu, L.5
  • 24
    • 66149091940 scopus 로고    scopus 로고
    • A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
    • Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
    • (2009) Cell , vol.137 , pp. 835-848
    • Luo, J.1
  • 25
    • 77954938591 scopus 로고    scopus 로고
    • Future of personalized medicine in oncology: A systems biology approach
    • Gonzalez-Angulo, A.M., Hennessy, B.T. & Mills, G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 2777-2783
    • Gonzalez-Angulo, A.M.1    Hennessy, B.T.2    Mills, G.B.3
  • 27
    • 72149101924 scopus 로고    scopus 로고
    • Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells
    • Jørgensen, C. et al. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-1509 (2009).
    • (2009) Science , vol.326 , pp. 1502-1509
    • Jørgensen, C.1
  • 28
    • 34250882643 scopus 로고    scopus 로고
    • Quantitative morphological signatures define local signaling networks regulating cell morphology
    • DOI 10.1126/science.1140324
    • Bakal, C., Aach, J., Church, G. & Perrimon, N. Quantitative morphological signatures define local signaling networks regulating cell morphology. Science 316, 1753-1756 (2007). (Pubitemid 46988551)
    • (2007) Science , vol.316 , Issue.5832 , pp. 1753-1756
    • Bakal, C.1    Aach, J.2    Church, G.3    Perrimon, N.4
  • 29
    • 54249117296 scopus 로고    scopus 로고
    • Phosphorylation networks regulating JNK activity in diverse genetic backgrounds
    • Bakal, C. et al. Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 322, 453-456 (2008).
    • (2008) Science , vol.322 , pp. 453-456
    • Bakal, C.1
  • 31
    • 59849106371 scopus 로고    scopus 로고
    • Protein promiscuity and its implications for biotechnology
    • Nobeli, I., Favia, A.D. & Thornton, J.M. Protein promiscuity and its implications for biotechnology. Nat. Biotechnol. 27, 157-167 (2009).
    • (2009) Nat. Biotechnol. , vol.27 , pp. 157-167
    • Nobeli, I.1    Favia, A.D.2    Thornton, J.M.3
  • 32
    • 70449673534 scopus 로고    scopus 로고
    • Drug discovery: Predicting promiscuity
    • Hopkins, A.L. Drug discovery: Predicting promiscuity. Nature 462, 167-168 (2009).
    • (2009) Nature , vol.462 , pp. 167-168
    • Hopkins, A.L.1
  • 33
    • 38049018155 scopus 로고    scopus 로고
    • A quantitative analysis of kinase inhibitor selectivity
    • Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
    • (2008) Nat. Biotechnol. , vol.26 , pp. 127-132
    • Karaman, M.W.1
  • 34
    • 80755125575 scopus 로고    scopus 로고
    • Comprehensive analysis of kinase inhibitor selectivity
    • Davis, M.I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
    • (2011) Nat. Biotechnol. , vol.29 , pp. 1046-1051
    • Davis, M.I.1
  • 35
    • 80755125565 scopus 로고    scopus 로고
    • Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
    • Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H. & Peterson, J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
    • (2011) Nat. Biotechnol. , vol.29 , pp. 1039-1045
    • Anastassiadis, T.1    Deacon, S.W.2    Devarajan, K.3    Ma, H.4    Peterson, J.R.5
  • 36
  • 38
    • 82255192307 scopus 로고    scopus 로고
    • Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects
    • Lötsch, J. & Geisslinger, G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov. Today 16, 1001-1006 (2011).
    • (2011) Drug Discov. Today , vol.16 , pp. 1001-1006
    • Lötsch, J.1    Geisslinger, G.2
  • 39
    • 84884162850 scopus 로고    scopus 로고
    • Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors
    • Kirouac, D.C. et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013).
    • (2013) Sci. Signal. , vol.6
    • Kirouac, D.C.1
  • 41
    • 78651287426 scopus 로고    scopus 로고
    • DrugBank 3.0: A comprehensive resource for 'omics' research on drugs
    • Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
    • (2011) Nucleic Acids Res. , vol.39
    • Knox, C.1
  • 43
    • 84862192766 scopus 로고    scopus 로고
    • ChEMBL: A large-scale bioactivity database for drug discovery
    • Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
    • (2012) Nucleic Acids Res. , vol.40
    • Gaulton, A.1
  • 45
    • 84856389509 scopus 로고    scopus 로고
    • RNA-based therapeutics: Current progress and future prospects
    • Burnett, J.C. & Rossi, J.J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-71 (2012).
    • (2012) Chem. Biol. , vol.19 , pp. 60-71
    • Burnett, J.C.1    Rossi, J.J.2
  • 46
    • 84874443644 scopus 로고    scopus 로고
    • Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo
    • Meng, H. et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7, 994-1005 (2013).
    • (2013) ACS Nano , vol.7 , pp. 994-1005
    • Meng, H.1
  • 47
    • 84866096861 scopus 로고    scopus 로고
    • Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
    • Bodenmiller, B. et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858-867 (2012).
    • (2012) Nat. Biotechnol. , vol.30 , pp. 858-867
    • Bodenmiller, B.1
  • 48
    • 84879796970 scopus 로고    scopus 로고
    • Circulating tumour cells and cell-free DNA as tools for managing breast cancer
    • Cortes, J. et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 10, 377-389 (2013).
    • (2013) Nat. Rev. Clin. Oncol. , vol.10 , pp. 377-389
    • Cortes, J.1
  • 50
    • 77954113465 scopus 로고    scopus 로고
    • Predicting and monitoring cancer treatment response with diffusion-weighted MRI
    • Thoeny, H.C. & Ross, B.D. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J. Magn. Reson. Imaging 32, 2-16 (2010).
    • (2010) J. Magn. Reson. Imaging , vol.32 , pp. 2-16
    • Thoeny, H.C.1    Ross, B.D.2
  • 51
    • 66149097035 scopus 로고    scopus 로고
    • Response to therapy in breast cancer
    • Avril, N., Sassen, S. & Roylance, R. Response to therapy in breast cancer. J. Nucl. Med. 50 (suppl. 1), 55S-63S (2009).
    • (2009) J. Nucl. Med. , vol.50 , Issue.SUPPL. 1
    • Avril, N.1    Sassen, S.2    Roylance, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.